Mmbg Investment Advisors CO. Has $5.60 Million Stock Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Mmbg Investment Advisors CO. lowered its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 46.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 42,324 shares of the financial services provider’s stock after selling 36,226 shares during the quarter. Mmbg Investment Advisors CO. owned approximately 0.09% of iShares Biotechnology ETF worth $5,596,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Guardian Wealth Advisors LLC NC lifted its holdings in iShares Biotechnology ETF by 24.8% during the fourth quarter. Guardian Wealth Advisors LLC NC now owns 372 shares of the financial services provider’s stock worth $49,000 after acquiring an additional 74 shares during the period. Ally Invest Advisors Inc. lifted its stake in iShares Biotechnology ETF by 5.3% during the fourth quarter. Ally Invest Advisors Inc. now owns 1,515 shares of the financial services provider’s stock worth $200,000 after purchasing an additional 76 shares during the last quarter. Arete Wealth Advisors LLC grew its holdings in shares of iShares Biotechnology ETF by 4.2% during the 4th quarter. Arete Wealth Advisors LLC now owns 1,990 shares of the financial services provider’s stock valued at $263,000 after purchasing an additional 80 shares during the last quarter. TD Private Client Wealth LLC boosted its stake in shares of iShares Biotechnology ETF by 3.0% during the fourth quarter. TD Private Client Wealth LLC now owns 2,746 shares of the financial services provider’s stock valued at $363,000 after purchasing an additional 81 shares during the period. Finally, Cullen Frost Bankers Inc. lifted its holdings in iShares Biotechnology ETF by 1.5% in the 4th quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock worth $748,000 after buying an additional 82 shares during the period. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of iShares Biotechnology ETF stock opened at $116.59 on Monday. The stock has a market cap of $5.10 billion, a price-to-earnings ratio of 25.09 and a beta of 0.84. The firm’s 50-day moving average is $125.40 and its 200 day moving average is $133.42. iShares Biotechnology ETF has a 1 year low of $107.43 and a 1 year high of $150.57.

iShares Biotechnology ETF Increases Dividend

The company also recently announced a dividend, which was paid on Friday, March 21st. Investors of record on Tuesday, March 18th were issued a $0.1212 dividend. This is a positive change from iShares Biotechnology ETF’s previous dividend of $0.06. The ex-dividend date of this dividend was Tuesday, March 18th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.